CLDX - Celldex Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CLDX is currently covered by 4 analysts with an average price target of $87.24. This is a potential upside of $62.76 (256.37%) from yesterday's end of day stock price of $24.48.

Celldex Therapeutics's activity chart (see below) currently has 62 price targets and 84 ratings on display. The stock rating distribution of CLDX is 88.24% BUY, 2.94% SELL and 8.82% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 22.66% with an average time for these price targets to be met of 69.36 days.

Highest price target for CLDX is $67, Lowest price target is $50, average price target is $61.

Most recent stock forecast was given by JOSEPH PANTGINIS from HC WAINWRIGHT on 16-Jun-2025. First documented stock forecast 19-Dec-2008.

Currently out of the existing stock ratings of CLDX, 30 are a BUY (88.24%), 1 are a SELL (2.94%), 3 are a HOLD (8.82%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$50

$24.5 (96.08%)

$50

2 months 2 days ago
(16-Jun-2025)

6/32 (18.75%)

$29.66 (145.82%)

256

Buy

$67

$41.5 (162.75%)

$67

6 months 20 days ago
(29-Jan-2025)

4/18 (22.22%)

$41.49 (162.64%)

62

Hold

$37

$11.5 (45.10%)

$35

1 years 6 days ago
(12-Aug-2024)

4/4 (100%)

$3.54 (10.58%)

165

Buy

$90

$64.5 (252.94%)

$72

1 years 5 months 22 days ago
(27-Feb-2024)

0/4 (0%)

$38.96 (76.33%)

Buy

$68

$42.5 (166.67%)

$70

2 years 7 days ago
(11-Aug-2023)

0/3 (0%)

$37.77 (124.94%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CLDX (Celldex Therapeutics) average time for price targets to be met?

On average it took 69.36 days on average for the stock forecasts to be realized with a an average price target met ratio 22.66

Which analyst has the current highest performing score on CLDX (Celldex Therapeutics) with a proven track record?

BIREN AMIN

Which analyst has the most public recommendations on CLDX (Celldex Therapeutics)?

Biren Amin works at PIPER SANDLER and has 5 price targets and 6 ratings on CLDX

Which analyst is the currently most bullish on CLDX (Celldex Therapeutics)?

Jonathan Aschoff with highest potential upside - $437.48

Which analyst is the currently most reserved on CLDX (Celldex Therapeutics)?

Mara Goldstein with lowest potential downside - -$22.5

Celldex Therapeutics in the News

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +1.16%. A quarter ago, it...

Celldex Therapeutics Inc (NASDAQ:CLDX) Q2 2025 Earnings: Revenue Misses, EPS Narrowly Beats Amid Strong Pipeline Progress

CELLDEX THERAPEUTICS INC (NASDAQ:CLDX [https://www.chartmill.com/stock/quote/CLDX]) REPORTS Q2 2025 EARNINGS: REVENUE MISSES ESTIMATES, EPS NARROWLY BEATS EXPECTATIONS Celldex Therapeutics Inc released its second-quarter 2025 financial results, reporting revenue of $730,000, falling short of analyst estimates of $1.03 million. The company’s earnings per share (EPS) came in at -$0.85, slightly better than the anticipated -$0.87. Despite the...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?